Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Risk of Bleeding With Dabigatran in 2010-2011 Medicare Data.

Literature DB >> 26146922

Risk of Bleeding With Dabigatran in 2010-2011 Medicare Data.

Inmaculada Hernandez¹, Yuting Zhang¹.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2015 PMID： 26146922 PMCID： PMC4495572 DOI： 10.1001/jamainternmed.2015.1299

Source DB: PubMed Journal: JAMA Intern Med ISSN： 2168-6106 Impact factor: 21.873

× No keyword cloud information.

6 in total

1. Risk of bleeding with dabigatran in atrial fibrillation.

Authors: Inmaculada Hernandez; Seo Hyon Baik; Antonio Piñera; Yuting Zhang
Journal: JAMA Intern Med Date: 2015-01 Impact factor: 21.873

2. A Methodological Appraisal of Recent Real-World Data Publications on Dabigatran.

Authors: Kristina Zint; Jörg Kreuzer
Journal: JAMA Intern Med Date: 2015-07 Impact factor: 21.873

3. One-Year Risk of Bleeding With Dabigatran in Patients With Atrial Fibrillation: Placing Real-World Results Into Perspective.

Authors: Marta A Miyares
Journal: JAMA Intern Med Date: 2015-07 Impact factor: 21.873

4. The Role of Selection in the Risk of Bleeding With Dabigatran in Patients With Atrial Fibrillation.

Authors: Adi Klil-Drori; Laurent Azoulay
Journal: JAMA Intern Med Date: 2015-07 Impact factor: 21.873

5. Patient Characteristics and Risk of Bleeding With Dabigatran in Atrial Fibrillation.

Authors: Daniel Pilsgaard Henriksen; Morten Rix Hansen; Per Damkier
Journal: JAMA Intern Med Date: 2015-07 Impact factor: 21.873

6. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.

Authors: David J Graham; Marsha E Reichman; Michael Wernecke; Rongmei Zhang; Mary Ross Southworth; Mark Levenson; Ting-Chang Sheu; Katrina Mott; Margie R Goulding; Monika Houstoun; Thomas E MaCurdy; Chris Worrall; Jeffrey A Kelman
Journal: Circulation Date: 2014-10-30 Impact factor: 29.690

6 in total

1. Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data.

Authors: Inmaculada Hernandez; Yuting Zhang
Journal: Am J Cardiovasc Drugs Date: 2017-02 Impact factor: 3.571

2. Thrombin Receptor Agonist Peptide-Induced Platelet Aggregation Is Reduced in Patients Receiving Dabigatran.

Authors: Frantisek Nehaj; Juraj Sokol; Michal Mokan; Jela Ivankova; Maros Mokan
Journal: Clin Appl Thromb Hemost Date: 2017-07-13 Impact factor: 2.389

3. Cost of Hospital Admissions in Medicare Patients With Atrial Fibrillation Taking Warfarin, Dabigatran, or Rivaroxaban.

Authors: Mary S Vaughan Sarrazin; Michael Jones; Alexander Mazur; Peter Cram; Padmaja Ayyagari; Elizabeth Chrischilles
Journal: J Am Coll Cardiol Date: 2017-01-24 Impact factor: 24.094